PsyBio Therapeutics Inc.
TSX-V: PSYB
Company Overview
PsyBio Therapeutics is a biotechnology company developing novel formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health and other disorders.
The team has experience in drug discovery based on synthetic biology as well as clinical and regulatory experience moving drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof.
The company is also researching and developing new non-naturally occurring molecular structures which may have unique therapeutics properties.
The team has experience in drug discovery based on synthetic biology as well as clinical and regulatory experience moving drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof.
The company is also researching and developing new non-naturally occurring molecular structures which may have unique therapeutics properties.
Financial Highlights
$0
Revenue (ttm)
-$1,562,500
Gross Profit (ttm)
-$0.07
Diluted EPS (ttm)
Management Team
Mr. Evan Mike Levine
Co-Founder, CEO & Chairman
Mr. Noah Isidore Davis
CFO, Sec. & Director
Dr. Michael Spigarelli M.B.A., M.B.E., M.D., Ph.D.
Chief Scientific Officer & Chief Medical Officer
Mr. Ross Carmel
Chief Legal Officer & Director
Mr. Andrew Jones
Inventor & Chairman of Scientific Advisory Board
Key Highlights
Market Capitalization
$0
Shares Outstanding
0
Shares Short (% of Float)
()
Insider Ownership
20%